Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

COCH vs CDRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDRE Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

CDRE Overall Winner 6-Pillar Tally: COCH 0 – 6 CDRE Matrix Metrics: COCH 2 – 8 CDRE

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas CDRE carries 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin).

  • Growth vs. Quality Trade-Off: CDRE earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. COCH 35.1/100 SELL) and 0.87β · 42% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both COCH (35.1/100 SELL) and CDRE (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCH vs CDRE
COCH NASDAQ
Envoy Medical, Inc. Class A Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$6.70
+0.0% 1D
Market Cap $51.9M
TTM Revenue $231,000
Forward P/E N/M
Beta / 30D Vol 4.94β · 3352% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (348.7% over 20 days), RSI 78
RSI-14: 77.7 · SMA20: $6.79 · SMA50: $3.12
CDRE NYSE Head-to-Head Winner
Cadre Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.45
-3.63% 1D
Market Cap $1.3B
TTM Revenue $733M
Forward P/E 18.5x
Beta / 30D Vol 0.87β · 42% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.7 · SMA20: $31.80 · SMA50: $28.53

6-Pillar Scorecard Institutional Category Breakdown (COCH 0 – 6 CDRE)

Columns: Metric · COCH · CDRE
1. Valuation Multiples CDRE
Forward P/E N/M 18.5x
Trailing P/E N/M 33.6x
PEG Ratio N/M N/M
EV / Revenue 119.2x 2.2x
2. Growth & Scale CDRE
Revenue Growth (YoY) +57.1% +30.2%
Earnings Growth (YoY) +0.0% +37.5%
TTM Revenue (USD) $231,000 $733M
Market Cap $51.9M $1.3B
3. Profitability & Quality CDRE
Gross Margin N/A 42.8%
Operating Margin -10261.0% 12.5%
Net Profit Margin 0.0% 5.6%
Return on Equity (ROE) 0.0% 11.6%
4. Balance Sheet & Cash Flow CDRE
Cash Generation (TTM) -$21M $76M
Cash Flow Margin N/A 10.4%
Net Cash / Leverage $24M Net Cash $330M Net Debt (1.08x D/E)
Dividend Yield None (0.00%) 1.24%
5. Options & Positioning CDRE
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 47.3% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat CDRE
OpEx & R&D Intensity N/A 30.3% of Rev ($222M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Aerospace & Defense Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCH (2) vs CDRE (8)
Institutional Metric COCH CDRE Criterion Row Edge
Market Capitalization
Scale
$51.9M $1.3B Larger Scale CDRE
Trailing P/E Ratio
Valuation
N/M 33.6x Lower Multiple CDRE
Forward P/E Ratio
Valuation
N/M 18.5x Lower Multiple CDRE
Revenue Growth (YoY)
Growth
+57.1% +30.2% Higher Growth COCH
Operating Margin (TTM)
Profitability
-10261.0% 12.5% Higher Margin CDRE
Net Profit Margin
Profitability
0.0% 5.6% Higher Margin CDRE
Return on Equity (ROE)
Capital Efficiency
0.0% 11.6% Higher ROE CDRE
52-Week Range Position
Momentum
89% ($0–$7) 22% ($24–$49) Stronger Trend COCH
Beta / 30D Volatility
Risk Regime
4.94β · 3352% Vol 0.87β · 42% Vol Lower Realized Risk CDRE
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 39.6 / 100 (SELL) Higher Composite CDRE
Trailing 12M Revenue (USD)
Operating Scale
$231,000 $733M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 119.2x EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($24M Net Cash) $76M ($330M Net Debt (1.08x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCH +1024.38 pp
COCH: +1024.35% · CDRE: -0.03%
3M Horizon COCH +808.85 pp
COCH: +797.88% · CDRE: -10.97%
6M Horizon COCH +847.83 pp
COCH: +844.99% · CDRE: -2.84%
1Y Horizon COCH +869.78 pp
COCH: +843.4% · CDRE: -26.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCH Revenue CDRE Revenue COCH Op. Margin CDRE Op. Margin Margin Leader
FY2020 N/A $400M N/A 12.3% CDRE
FY2021 N/A $430M N/A 12.1% CDRE
FY2022 $0M $460M -3673.4% 3.7% CDRE
FY2023 $0M $480M -5809.8% 11.7% CDRE
FY2024 $0M $570M -8558.2% 11.8% CDRE
FY2025 $0M $610M -9240.7% 11.0% CDRE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDRE SURGE
9d in phase · OBV DISTRIBUTION
Current IV 47.3%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CDRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDRE Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $1.3B market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 30.3% of Rev ($222M)
90D Engineering Disclosures 0 Published

Investor FAQ COCH vs CDRE Key Questions & Quantitative Answers

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas CDRE carries 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin). Growth vs. Quality Trade-Off: CDRE earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. COCH 35.1/100 SELL) and 0.87β · 42% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both COCH (35.1/100 SELL) and CDRE (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

CDRE leads the Growth & Scale pillar: COCH posts +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin), compared with CDRE at +30.2% YoY revenue growth and +37.5% YoY earnings growth on $733M TTM revenue (42.8% gross margin, 12.5% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), COCH cumulative revenue shifted N/A while CDRE shifted +52.5%. In operating R&D and SG&A reinvestment, COCH deploys N/A (0 90-day corporate R&D disclosures) versus 30.3% of Rev ($222M) (0 disclosures) for CDRE.

CDRE screens cheaper on headline valuation multiples. COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin), whereas CDRE trades at 18.5x Forward P/E, 33.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (10.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCH (0.0% ROE) versus CDRE (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk). By comparison, CDRE carries 47.3% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.87β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.